News

December 9, 2020December 9, 2020

Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets

News

Antengene is asking health authorities in Singapore, Australia, and Hong Kong to approve Xpovio (selinexor) for the treatment of multiple myeloma, the company announced in a press release. Specifically, ... Read more

December 7, 2020December 7, 2020

Dana-Farber, Quest Diagnostics Studying COVID-19 Prevalence in Myeloma

News

The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the prevalence of COVID-19 among individuals with or at risk of developing ... Read more

December 4, 2020December 4, 2020

FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A

News

The U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on a Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy, UCARTCS1A, for the treatment of ... Read more

November 25, 2020November 25, 2020

China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers

News

Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent bone problems — such as fractures, spinal cord compressions, and the need for radiation ... Read more

November 23, 2020November 24, 2020

New $100M Program Aims to Improve Diversity in Clinical Trials

News, syndicated

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved ... Read more

November 18, 2020November 18, 2020

Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU

News

Janssen is seeking to extend approval of its under-the-skin formulation of Darzalex (daratumumab) to include its use in combination with Pomalyst (pomalidomide) and dexamethasone to treat relapsed or refractory multiple myeloma patients who received ... Read more

November 16, 2020November 16, 2020

Myeloma UK Calls for More Data Transparency to Safeguard Patients From COVID-19

News

Myeloma UK is calling for more data transparency in government efforts to safeguard myeloma patients during the COVID-19 pandemic. This comes after results were released from its COVID-19 survey ... Read more

November 13, 2020November 13, 2020

Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715

News

ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people with relapsed or refractory multiple myeloma, a ... Read more

November 11, 2020November 11, 2020

Radiation Therapy Safe for Myeloma Patients Before CAR T-cell Infusion, Study Finds

News

Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to be manufactured was found to be safe and did not impact CAR ... Read more

November 9, 2020November 9, 2020

New Nirogacestat Combos to Enter Myeloma Trials, SpringWorks Says

News

SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents to treat people with relapsed or refractory multiple ... Read more